The global Thyroid Eye Disease (TED) market size is expanding rapidly, fueled by the advent of targeted immunotherapies and biologic molecules designed to address inflammatory orbitopathy. TED products offer clear advantages over traditional corticosteroids, including improved safety profiles, reduced recurrence rates, and enhanced patient quality of life.

As disease awareness grows and diagnostic technologies advance, clinicians increasingly rely on monoclonal antibodies and peptide-based immunomodulators to mitigate proptosis, diplopia, and orbital inflammation. Patient-centric treatment regimens, coupled with personalized dosing strategies, underscore the need for next-generation therapies that offer durable remission. Market research indicates substantial Thyroid Eye Disease (TED) Market opportunities in both first- and second-line settings, while market trends highlight a shift toward outpatient infusion centers and home-administered injections. Ongoing clinical trials and regulatory approvals are broadening market segments in North America, Europe, and Asia-Pacific, supporting robust business growth.

The Global Thyroid Eye Disease (TED) Market is estimated to be valued at USD 2.71 Billion in 2025 and is expected to reach USD 4.10 Billion by 2032, growing at a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032.

Key Takeaways

Key players operating in the Thyroid Eye Disease (TED) Market are Horizon Therapeutics, Immunovant, Viridian Therapeutics, Novartis, and Apitope. These market companies employ diverse market growth strategies—Horizon Therapeutics leverages its market share with Tepezza, Immunovant advances its monoclonal antibody program against IGF-1R, Viridian Therapeutics pursues T-cell modulation approaches, Novartis explores combination regimens with existing immunosuppressants, and Apitope focuses on peptide-based immunotherapies in late-stage trials. Their collective efforts are detailed in various market reports, providing in-depth market analysis, revenue forecasts, and competitive landscape insights.

➢Get More Insights On: Thyroid Eye Disease (TED) Market

➢Get this Report in Japanese Language: 甲状腺眼症TEDマーケット

➢Get this Report in Korean Language: 갑상선안구질환TED시장

➢Read More Related Articles- Single Use Downstream Bioprocessing: Poised to Garner Maximum Revenues During 2023-2033